Cancer

Cover image for Vol. 121 Issue 1

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/203 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 135
  1. Original Articles

    1. Discipline

      Radiation Oncology
      Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma

      Anne W.M. Lee, Roger K.C. Ngan, Stewart Y. Tung, Ashley Cheng, Dora L.W. Kwong, Tai-Xiang Lu, Anthony T.C. Chan, Lucy L.K. Chan, Harry Yiu, Wai-Tong Ng, Frank Wong, Kam-Tong Yuen, Stephen Yau, Foon-Yiu Cheung, Oscar S.H. Chan, Horace Choi and Rick Chappell

      Article first published online: 19 DEC 2014 | DOI: 10.1002/cncr.29208

      Preliminary results from nasopharyngeal carcinoma trial NPC-0501 demonstrate that the benefit of changing the chemotherapy schedule from a concurrent-adjuvant sequence to an induction-concurrent sequence remains uncertain, and replacing fluorouracil with capecitabine warrants further validation in view of the convenience and favorable toxicity profile of capecitabine and the at least comparable efficacy each agent. In agreement with studies on other head and neck cancers, accelerated fractionation is not recommended for patients with locoregionally advanced nasopharyngeal carcinoma who are receiving chemoradiotherapy.

  2. Review Articles

    1. Frailty in childhood cancer survivors

      Kirsten K. Ness, Gregory T. Armstrong, Mondira Kundu, Carmen L. Wilson, Tamara Tchkonia and James L. Kirkland

      Article first published online: 19 DEC 2014 | DOI: 10.1002/cncr.29211

      Young adult childhood cancer survivors are at an increased risk of frailty, a physiologic phenotype typically found among older adults. This phenotype is associated with new-onset chronic health conditions and mortality among both older adults and childhood cancer survivors. This article provides a review of the evidence documenting physiologic frailty among childhood cancer survivors and describes potential biological mechanisms for this phenotype.

  3. Original Articles

    1. Discipline

      Pediatric Oncology
      Safety and diagnostic accuracy of tumor biopsies in children with cancer

      Rodrigo B. Interiano, Amos H.P. Loh, Nathan Hinkle, Fazal N. Wahid, Alpin D. Malkan, Armita Bahrami, Jesse J. Jenkins, Shenghua Mao, Jianrong Wu, Kimberly Proctor, Victor M. Santana, Alberto S. Pappo, Robert E. Gold and Andrew M. Davidoff

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29167

      In addition to establishing the diagnosis of cancer, tumor biopsies are being increasingly used for determining the presence of molecular targets, confirming pharmacodynamic effects, and tumor banking. Nevertheless, to the authors' knowledge, the risks and accuracy of these procedures in pediatric patients with cancer are unknown. In the current review of an extensive experience, the authors found that tumor biopsies in children are associated with an acceptably low incidence of clinically relevant adverse events (<8%) and have a high diagnostic accuracy (>90%).

    2. Epidemiology
      Marital status and head and neck cancer outcomes

      Gino Inverso, Brandon A. Mahal, Ayal A. Aizer, R. Bruce Donoff, Nicole G. Chau and Robert I. Haddad

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29171

      Married patients are less likely than unmarried patients to present with metastatic oral and laryngeal cancers, more likely to receive definitive treatment across the 5 head and neck cancer sites (oral, oropharyngeal, hypopharyngeal, nasopharyngeal, and laryngeal), and less likely to die from cancers of these 5 sites. These findings suggest that spousal support may play a role in the surveillance of patients who have visual and symptomatic head and neck cancers and can lead to higher rates of treatment and better survival across all head and neck cancer types.

    3. Quality of Life
      The effects of cancer and racial disparities in health-related quality of life among older Americans: A case-control, population-based study

      Laura C. Pinheiro, Stephanie B. Wheeler, Ronald C. Chen, Deborah K. Mayer, Jessica C. Lyons and Bryce B. Reeve

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29205

      Although cancer diagnosis and treatment have a negative impact on individuals' lives regardless of race/ethnicity, among a group of patients with cancer (compared with a noncancer control group), the gap between racial/ethnic groups narrows before and after cancer diagnosis for some health-related quality-of-life measures. A greater understanding of the reasons why the racial/ethnic gap narrows is needed and can help inform initiatives to manage health-related quality of life among elderly cancer survivors in the United States.

    4. Disparities Research
      Practice adaptive reserve and colorectal cancer screening best practices at community health center clinics in 7 states

      Shin–Ping Tu, Vicki M. Young, Letoynia J. Coombs, Rebecca S. Williams, Michelle C. Kegler, Amanda T. Kimura, Betsy C. Risendal, Daniela B. Friedman, Beth A. Glenn, Debbie J. Pfeiffer and Maria E. Fernandez

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29176

      Enhancing the capability of community health centers to implement best practices may mitigate health disparities. A higher adaptive reserve, as measured by the practice adaptive reserve score, is positively associated with self-reported implementation of patient-centered medical home colorectal cancer screening best practices by clinic staff.

    5. Clinical Trials
      Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

      David J. Vaughn, Wei-Ting Hwang, Priti Lal, Mark A. Rosen, Maryann Gallagher and Peter J. O'Dwyer

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29213

      The retinoblastoma pathway is important in germ cell tumor biology and in the development of the platinum-resistant phenotype. In patients with incurable teratomas, the cyclin-dependent kinase 4/6 inhibitor palbociclib demonstrates promising activity, and further investigation is suggested.

  4. Commentary

    1. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

      Conor E. Steuer, Fadlo R. Khuri and Suresh S. Ramalingam

      Article first published online: 17 DEC 2014 | DOI: 10.1002/cncr.29139

      Resistance to first-generation and second-generation epidermal growth factor receptor (EGFR) inhibitors eventually develops in patients with EGFR-mutated non-small cell lung cancer. However, a new generation of EGFR inhibitors are currently in clinical trials and are demonstrating promising efficacy in this patient population.

    2. The importance of disclosure: Lesbian, gay, bisexual, transgender/transsexual, queer/questioning, and intersex individuals and the cancer continuum

      Gwendolyn P. Quinn, Matthew B. Schabath, Julian A. Sanchez, Steven K. Sutton and B. Lee Green

      Article first published online: 17 DEC 2014 | DOI: 10.1002/cncr.29203

  5. Erratum

    1. You have free access to this content
  6. Original Articles

    1. Disease Site

      Head and Neck Disease
      Increasing time to treatment initiation for head and neck cancer: An analysis of the National Cancer Database

      Colin T. Murphy, Thomas J. Galloway, Elizabeth A. Handorf, Lora Wang, Ranee Mehra, Douglas B. Flieder and John A. Ridge

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29191

      In a cohort of over 270,000 people in the National Cancer Database, the current study identifies trends and risk factors for the increasing time to initiation of definitive treatment for head and neck cancer in the United States.

    2. Gastrointestinal Disease
      RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer

      Rona Yaeger, Elizabeth Cowell, Joanne F. Chou, Alexandra N. Gewirtz, Laetitia Borsu, Efsevia Vakiani, David B. Solit, Neal Rosen, Marinela Capanu, Marc Ladanyi and Nancy Kemeny

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29196

      In an analysis of a large series of genetically annotated, metastatic colorectal cancer cases, we find that patients whose tumors harbor a RAS mutation experience shorter overall survival and a significantly higher cumulative incidence of brain, bone, and lung metastases, while the presence of a PIK3CA mutation does not predict for worse outcomes or a site-specific pattern of metastatic spread. These data suggest a role for RAS activation in tumor metastatic progression and may help inform physicians' assessment of symptoms in patients with metastatic colorectal cancer.

    3. Discipline

      Epidemiology
      Insurance status and risk of cancer mortality among adolescents and young adults

      Abby R. Rosenberg, Leah Kroon, Lu Chen, Christopher I. Li and Barbara Jones

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29187

      Adolescents and young adults with nonprivate insurance or no insurance are more likely to present with advanced stages of cancer at diagnosis and to have higher cancer-related mortality, even if they were diagnosed initially with lower stage disease. Broader insurance coverage and access to health care may improve some of the disparate outcomes of adolescents and young adults with cancer.

  7. Editorials

  8. Commentary

    1. Cancer disparities research: It is time to come of age

      Michael T. Halpern

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29192

      Although cancer disparities research has been an extremely productive field, much of this research has been largely descriptive. Researchers need to prioritize disparity areas with knowledge gaps and focus on understanding both the causes of and approaches to addressing and reducing disparities.

  9. Original Articles

    1. Discipline

      Outcomes Research
      Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals

      Uri Ladabaum, Ajitha Mannalithara, Lina Jandorf and Steven H. Itzkowitz

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29162

      Navigation increases uptake of screening colonoscopy among minority individuals. The results from this study suggest that navigation in a longitudinal screening colonoscopy program is likely to be cost effective, and that 1-time navigation in previously unscreened indivaduals may be cost saving.

    2. Disease Site

      Genitourinary Disease
      Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?

      Zachary Klaassen, Abhay A. Singh, Lauren E. Howard, Zhaoyong Feng, Bruce Trock, Martha K. Terris, William J. Aronson, Matthew R. Cooperberg, Christopher L. Amling, Christopher J. Kane, Alan Partin, Misop Han and Stephen J. Freedland

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29147

      The risk of biochemical recurrence for patients with clinical stage T2c disease without other high-risk features is comparable to the risk for men with intermediate-risk prostate cancer and significantly better than the risk for men with high-risk prostate cancer. Men with clinical stage T2c prostate cancer should be offered treatment options for intermediate-risk disease.

    3. Gastrointestinal Disease
      Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma

      William H. Sherman, Kyung Chu, John Chabot, John Allendorf, Beth Ann Schrope, Elizabeth Hecht, Brian Jin, David Leung, Helen Remotti, Gisella Addeo, Inna Postolov, Wei Tsai and Robert L. Fine

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29112

      Gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy can downstage more than 85% of patients with locally advanced pancreatic cancer so that more than 60% can achieve an R0 resection. This neoadjuvant regimen leads to a median survival greater than 29 months in those with arterial involvement, with more than 23% alive and disease-free beyond 32 months.

    4. Hematologic Malignancies
      Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project

      Bouthaina S. Dabaja, Ann M. Vanderplas, Allison L. Crosby-Thompson, Gregory A. Abel, Myron S. Czuczman, Jonathan W. Friedberg, Leo I. Gordon, Mark Kaminski, Joyce Niland, Michael Millenson, Auayporn P. Nademanee, Andrew Zelenetz, Ann S. LaCasce and Maria Alma Rodriguez

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29113

      The potential impact of consolidation on the overall survival and failure-free survival of patients with diffuse large B-cell lymphoma has been evaluated. Patients who receive consolidation radiation therapy are associated with a nonsignificant trend of higher overall survival and failure-free survival rates after adjustments for confounding factors.

    5. Breast Disease
      The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: Changes in practice patterns after publication of Cancer and Leukemia Group B 9343

      Manisha Palta, Priya Palta, Nrupen A. Bhavsar, Janet K. Horton and Rachel C. Blitzblau

      Article first published online: 8 DEC 2014 | DOI: 10.1002/cncr.28937

      Randomized phase 3 data from the Cancer and Leukemia Group B 9343 study support the omission of adjuvant radiotherapy in the treatment of elderly women with early-stage breast cancer. Analysis of practice patterns before and after the publication of these data indicates a significant decline in radiotherapy use. However, nearly two-thirds of women continue to receive adjuvant radiotherapy.

    6. Discipline

      Disparities Research
      US breast cancer mortality trends in young women according to race

      Foluso O. Ademuyiwa, Feng Gao, Lin Hao, Daniel Morgensztern, Rebecca L. Aft, Cynthia X. Ma and Matthew J. Ellis

      Article first published online: 5 DEC 2014 | DOI: 10.1002/cncr.29178

      Among young women diagnosed with breast cancer, black patients have a worse outcome than white patients. Mortality declines have been observed over time in both racial groups, although more rapid gains have been noted to occur among white women.

  10. Correspondence

    1. Reply to US lung cancer trends by histologic type

      Denise Riedel Lewis, William D. Travis and Susan S. Devesa

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29179

    2. US lung cancer trends by histologic type

      Manali I. Patel, Iona Cheng and Scarlett Lin Gomez

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29180

  11. Original Articles

    1. Discipline

      Disparities Research
      Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study

      Vishal Bhatnagar, Yin Wu, Olga G. Goloubeva, Kathleen T. Ruehle, Todd E. Milliron, Carolynn G. Harris, Aaron P. Rapoport, Saul Yanovich, Edward A. Sausville, Maria R. Baer and Ashraf Z. Badros

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29160

      In a retrospective review of patients with multiple myeloma treated at the study institution, there were notable differences in disease characteristics between black and white patients. Race also impacts overall survival, response to induction, and maintenance therapies.

    2. Clinical Trials
      SIS.NET: A randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer

      Alyse E. Wheelock, Meredith A. Bock, Eva L. Martin, Jimmy Hwang, Mary Lou Ernest, Hope S. Rugo, Laura J. Esserman and Michelle E. Melisko

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29088

      The results of this randomized controlled trial found that a Web-based system to facilitate symptom management among survivors of breast cancer did not lead to lower appointment frequency. However, Web-based tools to track patient symptoms may help to provide more efficient symptom management.

    3. Quality of Life
      Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation

      Areej R. El-Jawahri, Lara N. Traeger, Kailyn Kuzmuk, Justin R. Eusebio, Harry B. Vandusen, Jennifer A. Shin, Tanya Keenan, Emily R. Gallagher, Joseph A. Greer, William F. Pirl, Vicki A. Jackson, Karen K. Ballen, Thomas R. Spitzer, Timothy A. Graubert, Steven L. McAfee, Bimalangshu R. Dey, Yi-Bin A. Chen and Jennifer S. Temel

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29149

      Patients undergoing hematopoietic stem cell transplantation reported a steep deterioration in quality of life and substantially worsening depression during hospitalization. Baseline anxiety and depression were found to predict worse quality of life during hospitalization, underscoring the importance of assessing psychiatric morbidity prior to hematopoietic stem cell transplantation.

    4. Translational Research
      Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis

      Qiuling Shi, Xin Shelley Wang, Guojun Li, Nina D. Shah, Robert Z. Orlowski, Loretta A. Williams, Tito R. Mendoza and Charles S. Cleeland

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29154

      Predictors of symptom burden in patients with multiple myeloma after 1 year of therapy and possible associations between symptom burden and regulatory single-nucleotide polymorphisms in several inflammatory genes are investigated. Genetic markers may identify patients at risk for severe symptoms early in their cancer or treatment trajectory, and this could foster more effective symptom control.

    5. Disease Site

      Endocrine Disease
      Should small papillary thyroid cancer be observed? A population-based study

      Naris Nilubol and Electron Kebebew

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29123

      Nonoperative management should be used with caution for patients who have papillary thyroid cancers that measure ≤2 cm in greatest dimension. Patients aged ≥45 years with papillary thyroid cancers ≤2 cm should undergo thyroidectomy.

    6. Discipline

      Radiation Oncology
      A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer

      Penny Fang, Rosemarie Mick, Curtiland Deville, Stefan Both, Justin E. Bekelman, John P. Christodouleas, Thomas J. Guzzo, Zelig Tochner, Stephen M. Hahn and Neha Vapiwala

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29148

      In this patient-level, matched comparison of prospectively collected toxicity data on patietns with localized prostate carcinoma who received treated with contemporary IMRT and PBT techniques and similar dose-fractionation regimens, risks of acute and late GI and GU toxicities were not significantly different after careful adjustment for confounders and predictive factors.

  12. Erratum

    1. You have free access to this content
  13. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

      Frédéric Baron, Myriam Labopin, Andy Peniket, Pavel Jindra, Boris Afanasyev, Miguel A. Sanz, Eric Deconinck, Arnon Nagler and Mohamad Mohty

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29163

      Fludarabine and melphalan provide better acute myeloid leukemia control than fludarabine and busulfan as a reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation. Fludarabine plus busulfan and fludarabine plus melphalan provide similar overall survival.

    2. Discipline

      Epidemiology
      Metformin for primary colorectal cancer prevention in patients with diabetes: A case-control study in a US population

      Amikar Sehdev, Ya-Chen T. Shih, Benjamin Vekhter, Marc B. Bissonnette, Olufunmilayo I. Olopade and Blase N. Polite

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29165

      The use of metformin is associated with a reduced risk of developing colorectal cancer among patients with diabetes in the US population. Further studies are needed to understand the mechanism of action and the development of metformin for clinical use.

  14. Correspondence

  15. Erratum

    1. You have free access to this content
      Erratum

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29151

      This article corrects:
  16. Original Articles

    1. Disease Site

      Genitourinary Disease
      Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

      Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William K. Kelly and Howard L. McLeod

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29169

      The authors demonstrate that bevacizumab treatment is significantly associated with arterial thromboembolism (ATE) only, and not with venous thromboembolism (VTE). In addition, results from this study indicate that increasing age is significantly associated with the risk of both ATE and VTE in patients with prostate cancer, whereas the VTE risk score, which incorporates leukocyte count, hemoglobin, platelet count, body mass index, and tumor location, is significantly associated with the risk of VTE.

    2. Hematologic Malignancies
      Perinatal and familial risk factors for acute lymphoblastic leukemia in a Swedish national cohort

      Casey Crump, Jan Sundquist, Weiva Sieh, Marilyn A. Winkleby and Kristina Sundquist

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29172

      The authors conducted what to their knowledge is the largest population-based cohort study to date to examine perinatal and familial risk factors for acute lymphoblastic leukemia (ALL) among approximately 3.5 million individuals born in Sweden between 1973 and 2008. High fetal growth was found to be associated with an increased risk of ALL in childhood through young adulthood, independent of gestational age at birth, suggesting that growth factor pathways may play an important long-term role in the etiology of ALL.

  17. Editorials

    1. Bevicizumab and thrombosis: Some answers but questions remain

      Thomas G. DeLoughery and Tomasz M. Beer

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29168

      The study by Patel and colleagues reported in this issue verifies the increased risk of arterial thrombosis, but not venous thrombosis, with the receipt of bevacizumab. The focus of future research now needs to be on ameliorating this increased risk and identifying the mechanism for prothrombotic effects of targeted antineoplastic therapy.

  18. Original Articles

    1. Discipline

      Clinical Trials
      You have full text access to this OnlineOpen article
      Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors

      Johanna C. Bendell, Manish R. Patel, Jeffrey R. Infante, Carla D. Kurkjian, Suzanne F. Jones, Shubham Pant, Howard A. Burris III, Ofir Moreno, Vanessa Esquibel, Wendy Levin and Kathleen N. Moore

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29155

      The current phase 1, open-label, dose escalating, first-in human study of ME-344 in patients with refractory solid tumors found that the maximum tolerated dose of once-weekly 10-mg/kg administration of the drug was generally well tolerated. The preliminary clinical activity as a monotherapy supports the further clinical development of ME-344 in combination with chemotherapy.

    2. Epidemiology
      Quality of life over 5 years after a breast cancer diagnosis among low-income women: Effects of race/ethnicity and patient-physician communication

      Rose C. Maly, Yihang Liu, Li-Jung Liang and Patricia A. Ganz

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29150

      The current study is among the first and largest studies to examine risk factors for poorer quality of life among newly diagnosed, low-income women with breast cancer over time. The results suggest that quality of life in this vulnerable population could be particularly improved by targeted interventions aimed at increasing physician information-giving and empowering patients in communicating with physicians, as well as by attention to comorbid medical conditions.

    3. Disease Site

      Genitourinary Disease
      Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

      Daniel A. Hamstra, Kyounghwa Bae, Gerald Hanks, Chen Hu, William U. Shipley, Charlie C. Pan, Mack Roach III, Colleen A. Lawton and Howard M. Sandler

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29146

      After radiation therapy, biochemical failure is defined on the basis of either rising prostate-specific antigen levels or the initiation of salvage androgen ablation for other reasons. Patients started on salvage androgen therapy without meeting the criteria for rising prostate-specific antigen levels may have worse clinical outcomes; as such, those with rising prostate-specific antigen levels only may actually represent a more favorable group of patients.

    4. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer

      Hung-Jui Tan, Anne-Marie Meyer, Tzy-Mey Kuo, Angela B. Smith, Stephanie B. Wheeler, William R. Carpenter and Matthew E. Nielsen

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29144

      Provider-based research networks such as the Community Clinical Oncology Program offer a potential conduit for the diffusion of technology into the treatment of patients with cancer. However, the utilization of laparoscopy and partial nephrectomy for kidney cancer did not differ according to the Community Clinical Oncology Program affiliation status, and this indicates potential limits of provider-based research networks in translating evidence-based cancer care into clinical practice.

    5. Hematologic Malignancies
      Outcome of Patients With Low-Risk and Intermediate-1—Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure: A Report on Behalf of the MDS Clinical Research Consortium

      Elias J. Jabbour, Guillermo Garcia-Manero, Paolo Strati, Asmita Mishra, Najla H. Al Ali, Eric Padron, Jeffrey Lancet, Tapan Kadia, Naval Daver, Susan O'Brien, David P. Steensma, Mikkael A. Sekeres, Steven D. Gore, Amy Dezern, Gail J. Roboz, Alan F. List, Hagop M. Kantarjian and Rami S. Komrokji

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29145

      The outcomes of patients with lower-risk myelodysplastic syndromes after treatment failure with hypomethylating agents are poor, with a median survival of 17 months reported. Overall survival is a reasonable primary endpoint for clinical studies targeting this patient population.

  19. Editorials

    1. Struggles in exporting complex surgical advances

      Christopher Weight

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29143

      The diffusion of complex surgical innovations is challenging and slow and, in some cases, may not be in the patient's best interest. Perhaps better patient education and empowerment will allow the best care at lower cost.

  20. Original Articles

    1. Discipline

      Disparities Research
      Video-based educational tool improves patient comprehension of common prostate health terminology

      Daniel S. Wang, Ashesh B. Jani, Musu Sesay, Caroline G. Tai, Daniel K. Lee, Katharina V. Echt, Michael G. Goodman, Kerry E. Kilbridge and Viraj A. Master

      Article first published online: 12 NOV 2014 | DOI: 10.1002/cncr.29101

      Recent studies have revealed a disheartening lack of comprehension of medical terms often used in counseling patients about treatment options. To address this vital component of shared decision making, a video-based educational tool has been developed, and it results in significant gains in patient comprehension of such terminology.

    2. Disease Site

      Hematologic Malignancies
      Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?

      Fuad El Rassi, John D. Bergsagel, Martha Arellano, Manila Gaddh, Anand Jillella, Vamsi Kota, Leonard T. Heffner, Elliott F. Winton and Hanna Jean Khoury

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29142

      Flow cytometry (FC) is a commonly requested test in the workup of leukocytosis in community practices, and the role of FC in chronic-phase chronic myeloid leukemia (CP-CML) is unknown. In contrast to the detection of aberrant myeloid markers, the detection of lymphoid markers by FC at the time of the diagnosis of CP-CML appears to be associated with early progression to the lymphoid blast phase.

    3. Soft Tissue and Bone Sarcoma
      Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survival

      Jason U. Tilan, Mark Krailo, Donald A. Barkauskas, Susana Galli, Haifa Mtaweh, Jessica Long, Hongkun Wang, Kirsten Hawkins, Congyi Lu, Dima Jeha, Ewa Izycka-Swieszewska, Elizabeth R. Lawlor, Jeffrey A. Toretsky and Joanna B. Kitlinska

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29090

      Elevated systemic levels of neuropeptide Y, an EWS-FLI1 transcriptional target that is highly expressed in Ewing sarcoma, are associated with unfavorable clinical features, such as pelvic localization, the presence of metastases, and bone origin. Conversely, high activity of dipeptidyl peptidase IV in patients' sera is associated with a better prognosis, suggesting a potential role for the protease in antitumor immune response.

    4. Discipline

      Complementary Medicine
      Cancer survivors' disclosure of complementary health approaches to physicians: The role of patient-centered communication

      Stephanie J. Sohl, Laurel A. Borowski, Erin E. Kent, Ashley Wilder Smith, Ingrid Oakley-Girvan, Russell L. Rothman and Neeraj K. Arora

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29138

      Analyses of a population-based sample of cancer survivors support the idea that improving the overall patient centeredness of cancer follow-up care and improving the disclosure of complementary health approaches to physicians are potentially synergistic clinical goals.

    5. Disease Site

      Hematologic Malignancies
      Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

      Avichai Shimoni, Yulia Volchek, Maya Koren-Michowitz, Nira Varda-Bloom, Raz Somech, Noga Shem-Tov, Ronit Yerushalmi and Arnon Nagler

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29141

      Nilotinib is relatively safe and effective as prophylactic therapy for the prevention of relapse after allogeneic stem cell transplantation in the setting of advanced chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia.

  21. Erratum

    1. You have free access to this content
  22. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

      Meagan S. Barbee, Ajay Nooka, Jonathan L. Kaufman, Sungjin Kim, Zhengjia Chen, Leonard T. Heffner Jr, Sagar Lonial and R. Donald Harvey

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29136

      The findings of this study validate the use of the International Myeloma Working Group criteria in a phase 1 setting but bring into question the boundaries of response set forth by the criteria in a phase 1 population. It is suggested that normalization of the free light chain ratio be considered in future phase 1 studies as an early indicator of response to promote rapidity in moving novel therapies and combinations into the phase 2 evaluation.

    2. Discipline

      Clinical Trials
      Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

      Robert C. Doebele, David Spigel, Mustapha Tehfe, Sachdev Thomas, Martin Reck, Sunil Verma, Janice Eakle, Frederique Bustin, Jerome Goldschmidt Jr, Dachuang Cao, Ekaterine Alexandris, Sergey Yurasov, D. Ross Camidge and Philip Bonomi

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29132

      Although a statistically significant improvement in progression-free survival is not achieved in this phase 2 randomized study, ramucirumab shows evidence of clinical activity in combination with pemetrexed-platinum chemotherapy in patients with nonsquamous non–small cell lung cancer. The addition of ramucirumab does not result in new or unexpected safety findings.

    3. Disparities Research
      A mixed-methods examination of communication between oncologists and primary care providers among primary care physicians in underserved communities

      Megan Johnson Shen, Maria Binz-Scharf, Tom D'Agostino, Natasha Blakeney, Elisa Weiss, Margo Michaels, Shilpa Patel, M. Diane McKee and Carma L. Bylund

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29131

      Primary care physicians (PCPs) treating underserved, minority patients want to be more involved in patient care during and after cancer treatment, but significant communication gaps occur between oncologists and PCPs during this time. A focus on improving PCP-oncologist communication during treatment could reduce the burden on oncologists and improve patient satisfaction and care, specifically among underserved, minority populations.

    4. Epidemiology
      The rise in metastasectomy across cancer types over the past decade

      Edmund K. Bartlett, Kristina D. Simmons, Heather Wachtel, Robert E. Roses, Douglas L. Fraker, Rachel R. Kelz and Giorgos C. Karakousis

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29134

      From 2000 through 2011, metastasectomy was increasingly performed for patients with colorectal cancer, lung cancer, breast cancer, and melanoma. Inpatient mortality decreased despite increasing patient comorbidity. The increased performance of metastasectomy was predominately driven by high-volume institutions.

    5. Disease Site

      Soft Tissue and Bone Sarcoma
      Significant association between human osteosarcoma and simian virus 40

      Elisa Mazzoni, Maria Serena Benassi, Alfredo Corallini, Giovanni Barbanti-Brodano, Angelo Taronna, Piero Picci, Giovanni Guerra, Antonio D'Agostino, Lorenzo Trevisiol, Pier Francesco Nocini, Maria Vittoria Casali, Giuseppe Barbanti-Brodano, Fernanda Martini and Mauro Tognon

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29137

      Patients with osteosarcoma carry at high prevalence of simian virus 40 antibodies. The results of the current study indicate that these patients could be treated with antivirals.

    6. Discipline

      Psychosocial Oncology
      Experiencing reproductive concerns as a female cancer survivor is associated with depression

      Jessica R. Gorman, H. Irene Su, Samantha C. Roberts, Sally A. Dominick and Vanessa L. Malcarne

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29133

      Addressing the reproductive concerns experienced by young adult female cancer survivors is an important element of comprehensive survivorship care and has the potential to improve psychosocial health.

    7. Epidemiology
      Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: A study of the Veterans Affairs health care system

      Jose P. Zevallos, Christine M. Hartman, Jennifer R. Kramer, Erich M. Sturgis and Elizabeth Y. Chiao

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29122

      Although the incidence of thyroid cancer has doubled within the Veterans Affairs health care system, a nearly 5-fold increase in the use of thyroid ultrasound and a nearly 7-fold increase in the use of fine-needle aspiration occurred between 2000 and 2012. These findings suggest that the increase in thyroid cancer incidence may be related to increases in the use of ultrasound and fine-needle aspiration.

    8. Outcomes Research
      Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system–directed therapy

      Cara I. Kimberg, James L. Klosky, Nan Zhang, Tara M. Brinkman, Kirsten K. Ness, Deo Kumar Srivastava, Leslie L. Robison, Melissa M. Hudson and Kevin R. Krull

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29121

      Survivors of childhood cancer treated with central nervous system–directed therapy are at risk for poor health care utilization in part because of reduced global cognition. Educational approaches regarding recommended health care should be modified to ensure comprehension by survivors with neurocognitive impairment.

    9. Disease Site

      Gastrointestinal Disease
      Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?

      Timothy J. Price, Carol Beeke, Shahid Ullah, Robert Padbury, Guy Maddern, David Roder, Amanda R. Townsend, James Moore, Amitesh Roy, Yoko Tomita and Christos Karapetis

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29129

      The primary site of metastatic colorectal cancer impacts survival outcomes. Stratification by left and right colon should be considered in trial design.

    10. Discipline

      Outcomes Research
      Critical evaluation of the scientific content in clinical practice guidelines

      Zaid M. Abdelsattar, Bradley N. Reames, Scott E. Regenbogen, Samantha Hendren and Sandra L. Wong

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29124

      There is significant variation in the development processes and scientific content of clinical practice guidelines. Differences in interpreting the evidence and conflicting recommendations call for improving the quality and consistency of guidelines.

    11. Quality of Life
      Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: A population-based, case-control study

      Caroleen Quach, Hanna K. Sanoff, Grant R. Williams, Jessica C. Lyons and Bryce B. Reeve

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29125

      Older Americans with colorectal cancer, particularly later-stage patients, experience significant decrements in physical and mental health aspects of health-related quality of life, including activities of daily living impairment and being at greater risk for major depressive disorder, following diagnosis and treatment compared to matched noncancer controls.

    12. Psychosocial Oncology
      Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care

      Lynne I. Wagner, Julian Schink, Michael Bass, Shalini Patel, Maria Varela Diaz, Nan Rothrock, Timothy Pearman, Richard Gershon, Frank J. Penedo, Steven Rosen and David Cella

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29104

      The successful implementation of an electronic patient-reported outcome (ePRO) system using the Patient Reported Outcomes Measurement Information System is demonstrated for the precise, valid, and robust measurement of common cancer-related symptoms with electronic health record integration for immediate clinician notification and with triage for identified problems. Six hundred thirty-six gynecologic oncology outpatients complete the ePRO assessment, and they demonstrate its feasibility and provide information on the most common symptom-related and psychosocial concerns.

  23. Editorials

    1. Inherited predisposition to endometrial cancer: Moving beyond Lynch syndrome

      Zsofia K. Stadler and Mark E. Robson

      Article first published online: 5 NOV 2014 | DOI: 10.1002/cncr.29107

      A number of predisposition syndromes include endometrial cancer as a component tumor. These can generally be identified on the basis of the family history and the individual phenotype.

  24. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with cowden and cowden-like syndromes: An international, multicenter, prospective study

      Haider Mahdi, Jessica L. Mester, Emily A. Nizialek, Joanne Ngeow, Chad Michener and Charis Eng

      Article first published online: 5 NOV 2014 | DOI: 10.1002/cncr.29106

      In this prospective study of endometrial cancer patients with the Cowden phenotype, clinical predictors of a germline phosphatase and tensin homolog (PTEN) mutation include a younger age, macrocephaly, a high Cleveland Clinic score, a low PTEN protein level, and coexisting renal cancer. Endometrial cancer patients with germline KLLN promoter methylation are likely to have an increased phenotypic load and to present at younger ages similarly to those with a germline PTEN mutation. Thus, high-risk cancer surveillance and prophylactic surgery of the uterus may be considered for these patients similarly to those with PTEN mutations.

    2. Discipline

      Outcomes Research
      Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage

      Erin E. Kent, Anita Ambs, Sandra A. Mitchell, Steven B. Clauser, Ashley Wilder Smith and Ron D. Hays

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29119

      The health-related quality of life of older adult survivors of less common cancers is compared to the health-related quality of life of older individuals with no cancer history on the basis of data from the Surveillance, Epidemiology, and End Results/Medicare Health Outcomes Survey linked data resource. Inferior health-related quality of life (particularly impaired physical health) is found among survivors of several cancer types; the greatest deficits are reported by those with multiple myeloma and pancreatic cancer.

    3. The symptom burden of treatment-naive patients with head and neck cancer

      Ehab Y. Hanna, Tito R. Mendoza, David I. Rosenthal, G. Brandon Gunn, Pamela Sehra, Emre Yucel and Charles S. Cleeland

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29097

      Moderate to severe symptoms were found to be highly prevalent in the current study of treatment-naive patients with head and neck cancer, thereby demonstrating the importance of pretreatment symptom assessment and the need for symptom management together with disease treatment. Knowledge of disease-related (treatment-naive) symptom status is critical for evaluating the symptomatic benefit/burden of therapies for head and neck cancer.

    4. Disease Site

      Soft Tissue and Bone Sarcoma
      Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors

      Roger T. Anderson, Cyllene R. Morris, Gretchen Kimmick, Amy Trentham-Dietz, Fabian Camacho, Xiao-Cheng Wu, Susan A. Sabatino, Steven T. Fleming and Joseph Lipscomb

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29092

      In a large national database, the likelihood of receiving guideline-concordant care among patients with nonmetastatic breast cancer is lower with older age and with public insurance versus private insurance. Radiation therapy is the most omitted treatment component. Patient navigation targeted at high-risk or vulnerable patients may be needed to ensure access to high-quality care.

    5. Discipline

      Psychosocial Oncology
      You have full text access to this OnlineOpen article
      Mindfulness-based cancer recovery and supportive-expressive therapy maintain telomere length relative to controls in distressed breast cancer survivors

      Linda E. Carlson, Tara L. Beattie, Janine Giese-Davis, Peter Faris, Rie Tamagawa, Laura J. Fick, Erin S. Degelman and Michael Speca

      Article first published online: 3 NOV 2014 | DOI: 10.1002/cncr.29063

      Psychosocial interventions providing stress reduction and emotional support resulted in a trend toward telomere length maintenance in distressed breast cancer survivors compared with decreases in usual care. To the authors' knowledge, this is the first study to investigate the potential for short-term interventions to affect this important biomarker, but the clinical implications of the finding require further exploration.

  25. Review Articles

    1. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors

      Smita Bhatia

      Article first published online: 29 OCT 2014 | DOI: 10.1002/cncr.29096

      Treatment-related second cancers are a major cause of morbidity in cancer survivors. This review describes the current state of knowledge regarding the role of genetic susceptibility in the development of treatment-related second cancers.

    2. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

      Curtis R. Pickering, Robert C. Bast Jr and Khandan Keyomarsi

      Article first published online: 29 OCT 2014 | DOI: 10.1002/cncr.29033

      Medical advances happen only as a result of successful translational research endeavors, which are built on a foundation of basic science. Investigators with a deep understanding of fundamental biology and the mechanisms of disease are essential for translating laboratory discoveries into new and improved health interventions, diagnostics, and treatments. A failure to support basic scientists in translational research will slow the progress of modern medical advances.

  26. Original Articles

    1. Discipline

      Clinical Trials
      Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma

      Ethan Toumishey, Angeli Prasad, Greg Dueck, Neil Chua, Daygen Finch, James Johnston, Richard van der Jagt, Doug Stewart, Darrell White, Andrew Belch and Tony Reiman

      Article first published online: 29 OCT 2014 | DOI: 10.1002/cncr.29103

      Lenalidomide monotherapy demonstrates clinically relevant activity in patients with T-cell lymphoma and has a good safety profile. Lenalidomide has excellent potential as an agent in combination therapy for patients with T-cell lymphoma.

    2. Pathology
      Analysis of thyroid malignant pathologic findings identified during 3 rounds of screening (1997-2008) of a cohort of children and adolescents from belarus exposed to radioiodines after the Chernobyl accident

      Lydia B. Zablotska, Eldar A. Nadyrov, Alexander V. Rozhko, Zhihong Gong, Olga N. Polyanskaya, Robert J. McConnell, Patrick O'Kane, Alina V. Brenner, Mark P Little, Evgenia Ostroumova, Andre Bouville, Vladimir Drozdovitch, Viktor Minenko, Yuri Demidchik, Alexander Nerovnya, Vassilina Yauseyenka, Irina Savasteeva, Sergey Nikonovich, Kiyohiko Mabuchi and Maureen Hatch

      Article first published online: 28 OCT 2014 | DOI: 10.1002/cncr.29073

      In the largest series of thyroid cancers identified through systematic screening of children and adolescents from Belarus who were exposed to radioactive iodine from fallout after the Chernobyl accident in 1986, radiation doses to the thyroid gland are associated with histopathologic features of tumor aggressiveness, a higher probability of multifocal cancers, and a higher probability of solid and diffuse sclerosing variants of thyroid cancer pathology.

  27. Editorial

    1. Systematic screening after Chernobyl: Insights on radiation-induced thyroid cancer

      Linwah Yip and Sally E. Carty

      Article first published online: 28 OCT 2014 | DOI: 10.1002/cncr.29074

      Radiation-induced thyroid cancer remains an important public health issue after the Chernobyl accident. A systematic screening of the at-risk population provides new insights into the dose-dependent and time-dependent histologic features of the diagnosed thyroid cancers.

  28. Review Articles

    1. Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?

      Elisavet Paplomata, Rita Nahta and Ruth M. O'Regan

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29060

      Patients with small human epidermal growth factor receptor 2 (HER2)-positive cancers have an excellent outcome when treated with trastuzumab-based chemotherapy, suggesting that less aggressive treatment approaches may be appropriate for some patients. HER2-positive cancers that coexpress hormone receptors are heterogenous, and a subset appear to be driven at least in part by estrogen receptor and may be optimally treated with coinhibition of estrogen receptor and HER2 rather than chemotherapy.

  29. Original Articles

    1. Discipline

      Translational Research
      Clinical next-generation sequencing in patients with non–small cell lung cancer

      Ian S. Hagemann, Siddhartha Devarakonda, Christina M. Lockwood, David H. Spencer, Kalin Guebert, Andrew J. Bredemeyer, Hussam Al-Kateb, TuDung T. Nguyen, Eric J. Duncavage, Catherine E. Cottrell, Shashikant Kulkarni, Rakesh Nagarajan, Karen Seibert, Maria Baggstrom, Saiama N. Waqar, John D. Pfeifer, Daniel Morgensztern and Ramaswamy Govindan

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29089

      In a series of 381 consecutive non–small cell lung cancers submitted for clinical targeted next-generation sequencing, sequencing was successfully completed in 209 (55%) and resulted in the adoption of a targeted therapy in 22 (11%).

  30. Commentary

    1. Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules

      Joëlle Guilhot, Claude Preudhomme, Francois Xavier Mahon and François Guilhot

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29053

      Clinical trials for chronic myeloid leukemia frequently rely on molecular response as an outcome measurement. Unfortunately, as a surrogate marker, molecular response brings with it limitations related to both laboratory techniques as well as disease parameters.

  31. Original Articles

    1. Disease Site

      Genitourinary Disease
      Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility

      Phillip J. Gray, Chun Chieh Lin, Helmneh Sineshaw, Jonathan J. Paly, Ahmedin Jemal and Jason A. Efstathiou

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29094

      In an analysis of 34,067 patients with stage I testicular seminoma, the rate of observation after orchiectomy increases from 23.7% in 1998 to 54.0% in 2011. Racial minorities, the uninsured, and those treated at academic centers are more likely to receive observation.

    2. Discipline

      Pediatric Oncology
      Cancer-related follow-up care among hispanic and non-Hispanic childhood cancer survivors: The project forward study

      Joel E. Milam, Kathleen Meeske, Rhona I. Slaughter, Sandra Sherman-Bien, Anamara Ritt-Olson, Aura Kuperberg, David R. Freyer and Ann S. Hamilton

      Article first published online: 23 OCT 2014 | DOI: 10.1002/cncr.29105

      Follow-up care is critical for childhood cancer survivors who are at high risk for comorbidities and late effects of cancer treatments. Among 193 recently treated childhood cancer survivors, those who were Hispanic, older, or missing health insurance were at higher risk for lacking cancer follow-up care.

    3. Psychosocial Oncology
      Association between serious psychological distress and health care use and expenditures by cancer history

      Xuesong Han, Chun Chieh Lin, Chunyu Li, Janet S. de Moor, Juan L. Rodriguez, Erin E. Kent and Laura P. Forsythe

      Article first published online: 23 OCT 2014 | DOI: 10.1002/cncr.29102

      Serious psychological distress is reported to be associated with adverse health outcomes such as poor quality of life and shorter survival in cancer survivors. In a national representative sample of cancer survivors, serious psychological distress was found to be associated with higher health care use and medical expenditures.

  32. Editorial

    1. Revisiting structure, process, and outcome

      Scott M. Gilbert

      Article first published online: 22 OCT 2014 | DOI: 10.1002/cncr.29070

      The quality of bladder cancer varies markedly, and bladder cancer has not garnered national attention despite the incidence and cost burden associated with bladder cancer. This editorial argues for revisiting Donabedian's structure, process, and outcome framework for quality assessment among patients with bladder cancer.

  33. Original Articles

    1. Disease Site

      Genitourinary Disease
      Quality of diagnostic staging in patients with bladder cancer: A process-outcomes link

      Karim Chamie, Eric Ballon-Landa, Jeffrey C. Bassett, Timothy J. Daskivich, Meryl Leventhal, Dennis Deapen and Mark S. Litwin

      Article first published online: 22 OCT 2014 | DOI: 10.1002/cncr.29071

      The medical records of 1865 patients with bladder cancer in Los Angeles County are reviewed, and suboptimal staging in nearly half of all diagnostic resections is found to be associated with increased mortality, particularly in patients with high-grade disease.

    2. Head and Neck Disease
      Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status

      Shao Hui Huang, John N. Waldron, Michael Milosevic, Xiaowei Shen, Jolie Ringash, Jie Su, Li Tong, Bayardo Perez-Ordonez, Ilan Weinreb, Andrew J. Bayley, John Kim, Andrew Hope, B.C. John Cho, Meredith Giuliani, Albiruni Razak, David Goldstein, Willa Shi, Fei-Fei Liu, Wei Xu and Brian O'Sullivan

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29100

      This relatively large cohort study reports an intriguing hypothesis-generating observation: high pretreatment neutrophil counts, high pretreatment monocyte counts, and low pretreatment lymphocyte counts independently predict inferior survival and disease control for human papillomavirus–positive oropharyngeal cancer patients, whereas a predictive value for human papillomavirus–negative patients is not apparent.

  34. Review Articles

    1. Small cell lung cancer: Where do we go from here?

      Lauren Averett Byers and Charles M. Rudin

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29098

      The treatment of small cell lung cancer has not changed significantly in 3 decades. In this review, the authors discuss the current challenges and opportunities to accelerate progress in this highly lethal disease.

    2. Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

      Ursula A. Matulonis, Amit M. Oza, Tony W. Ho and Jonathan A. Ledermann

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29082

      Overall survival is regarded as the most clinically relevant endpoint in trials of ovarian cancer, but it may be confounded by multiple lines of subsequent therapy. A primary endpoint of progression-free survival supported by intermediate clinical endpoints and overall survival provides a more comprehensive approach for evaluating efficacy.

  35. Editorials

    1. Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

      Janet E. Dancey

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29084

      Intermediate endpoints that better capture the benefits of treatment and patient outcomes will facilitate trial conduct and ultimately treatment decisions for individual patients. Whether the current crop of newer endpoints will improve trial conduct and the interpretation of outcomes will require further evaluation.

  36. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

      Jean-Pierre Issa, Guillermo Garcia-Manero, Xuelin Huang, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce and Hagop M. Kantarjian

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29085

      For this randomized study, a Bayesian design is used to compare decitabine with decitabine plus valproic acid in patients with myelodysplastic syndrome and in elderly patients with acute myelogenous leukemia. No benefit is demonstrated from the addition of valproic acid; and the toxicity of the combination—particularly neurotoxicity—is more significant.

  37. Editorials

    1. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges

      Michael Lübbert and Andrea Kuendgen

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29083

      In the first randomized trial of older patients with myelodysplastic syndrome/acute myeloid leukemia (adaptive randomization) to receive treatment with intravenous decitabine (5-day schedule) either alone or in combination with the oral histone deacetylase (HDAC) inhibitor valproic acid (7-day schedule), Issa and colleagues do not detect an improved response rate or overall survival with the combined treatment. The various factors potentially affecting clinical outcome in studies combining decitabine or 5-azacytidine with valproic acid or other HDAC inhibitors are discussed.

  38. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer

      Aalok Kumar, Hagen F. Kennecke, Daniel J. Renouf, Howard J. Lim, Sharlene Gill, Ryan Woods, Caroline Speers and Winson Y. Cheung

      Article first published online: 20 OCT 2014 | DOI: 10.1002/cncr.29072

      Stage II colon cancer has a relatively good prognosis. Patients who have high-risk disease based on clinical and pathological factors may derive benefit from adjuvant chemotherapy in the setting of specific high-risk features such as T4 disease.

    2. Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

      Sant P. Chawla, Victoria S. Chua, Andrew F. Hendifar, Doris V. Quon, Neelesh Soman, Kamalesh K. Sankhala, D. Scott Wieland and Daniel J. Levitt

      Article first published online: 13 OCT 2014 | DOI: 10.1002/cncr.29081

      At the maximum tolerated dose of 350 mg/m2, aldoxorubicin demonstrates clinical activity in patients with recurrent or refractory advanced solid tumors, including soft tissue sarcomas, without evidence of acute cardiotoxicity, which is a major limitation to the use of native doxorubicin. Aldoxorubicin may allow for higher dose equivalents of doxorubicin to be administered.

    3. Discipline

      Epidemiology
      Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes

      Julie Hallet, Calvin How Lim Law, Moises Cukier, Refik Saskin, Ning Liu and Simron Singh

      Article first published online: 13 OCT 2014 | DOI: 10.1002/cncr.29099

      Although the incidence of all neuroendocrine tumors has markedly increased over the course of 15 years, the proportion of metastatic disease at presentation has decreased, and this points toward increased detection outlining a rise in incidence. Socioeconomic status and rural residency portend worse survival for patients with neuroendocrine tumors, and they should be paid particular attention when initiatives are being designed to improve care for patients with neuroendocrine tumors.

    4. Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohort

      Won Jin Ho, Michael S. Simon, Vedat O. Yildiz, James M. Shikany, Ikuko Kato, Jennifer L. Beebe-Dimmer, Jeremy P. Cetnar and Cathryn H. Bock

      Article first published online: 9 OCT 2014 | DOI: 10.1002/cncr.29091

      Increased lycopene intake among postmenopausal women is associated with a lower risk of renal cell carcinoma in the Women's Health Initiative cohort. Further investigation into the correlation between lycopene intake and the risk of renal cell carcinoma is warranted.

    5. Radiation Oncology
      A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy

      Jeremy Setton, Nancy Y. Lee, Nadeem Riaz, Shao-Hui Huang, John Waldron, Brian O'Sullivan, Zhigang Zhang, Weij Shi, David I. Rosenthal, Katherine A. Hutcheson and Adam S. Garden

      Article first published online: 6 OCT 2014 | DOI: 10.1002/cncr.29022

      In a multi-institution study of severe swallowing dysfunction requiring enteral support, patients are identified who previously received intensity-modulated radiotherapy with or without systemic therapy for oropharyngeal cancer. The results indicate that modern nonsurgical therapy for oropharyngeal cancer is associated with a low rate of long-term gastrostomy tube dependence.

  39. Review Articles

    1. Imaging of the axilla before preoperative chemotherapy: Implications for postmastectomy radiation

      Jose G. Bazan and Julia White

      Article first published online: 6 OCT 2014 | DOI: 10.1002/cncr.28859

      The decision to use postmastectomy radiotherapy for patients with breast cancer who receive neoadjuvant chemotherapy (NAC) is determined by the clinical extent of disease at presentation before NAC, the presence of pathologic residual disease (especially pathologically involved lymph nodes) after NAC, and the disease response to NAC. Therefore, accurate knowledge of the extent of axillary disease before NAC and assessment of response to therapy are critically important.

  40. Original Articles

    1. Disease Site

      Head and Neck Disease
      Prevalence and prognostic value of human papillomavirus genotypes in tonsillar squamous cell carcinoma: A Korean multicenter study

      Jae Hong No, Myung-Whun Sung, J. Hun Hah, Seung Ho Choi, Myung-Chul Lee, Hee Seung Kim and Yong-Sang Song

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29086

      The proportion of human papillomavirus–positive tonsillar cancer has increased during the last 20 years in Korea. The presence of human papillomavirus 18 may serve as a biomarker for a poor prognosis.

    2. Hematologic Malignancies
      Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

      Mohamad Mohty, Florent Malard, Didier Blaise, Noel Milpied, Sabine Furst, Resa Tabrizi, Thierry Guillaume, Stéphane Vigouroux, Jean El-Cheikh, Jacques Delaunay, Steven Le Gouill, Philippe Moreau, Myriam Labopin and Patrice Chevallier

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29087

      The reduced toxicity regimen based on a busulfan dose of 130 mg/m2/day intravenously for 3 days, fludarabine at a dose of 30 mg/m2/day for 5 days, and antithymocyte globulins at a dose of 2.5 mg/kg/day for 2 days was evaluated in a prospective phase 2 trial. This regimen appeared to be safe, with a low nonrecurrence mortality rate at 2 years in high-risk patients, and efficient disease control, thereby warranting prospective phase 3 trials.

    3. Discipline

      Outcomes Research
      Smoking history predicts for increased risk of second primary lung cancer: A comprehensive analysis

      John M. Boyle, Daniel J. Tandberg, Junzo P. Chino, Thomas A. D'Amico, Neal E. Ready and Chris R. Kelsey

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29095

      The current study identifies and quantifies risk factors for second primary lung cancer in a population of patients treated for an index non-small cell lung cancer. Among 1484 subjects, it was found that smoking was the only risk factor assessed that predicted for the development of a second primary lung cancer, with never-smokers having an exceedingly low risk.

  41. Editorials

    1. Targeted survival improvements in clinical trials: Are you an absolutist or relativist?

      James Paul

      Article first published online: 2 OCT 2014 | DOI: 10.1002/cncr.29031

      In this issue of Cancer, Castonguay et al highlights problems with reliably estimating the median OS in the control arm of clinical trials in ovarian cancer. This suggests that more careful reflection is genrally required concerning how clinically relevant differences are determined and highlights further issues with the selection of overall survival as a primary endpoint. The article also raises questions regarding the prevalent standard statistical approach used to design and analyze studies with time to event outcomes.

  42. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

      Vincent Castonguay, Michelle K. Wilson, Ivan Diaz-Padilla, Lisa Wang and Amit M. Oza

      Article first published online: 2 OCT 2014 | DOI: 10.1002/cncr.29030

      The anticipated clinical outcome of the standard/control arm is an important parameter in the design of randomized phase 3 trials for the accurate calculation of sample size, power, and study duration but is often underestimated in ovarian cancer trials. Changing patterns of care and variations in enrolled study populations may result in a deviation from the anticipated outcome and subsequent inaccurate statistical assumptions.

    2. Discipline

      Medical Oncology
      Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

      Liza C. Villaruz, Mark A. Socinski, Shira Abberbock, Lynne D. Berry, Bruce E. Johnson, David J. Kwiatkowski, A. John Iafrate, Marileila Varella-Garcia, Wilbur A. Franklin, D. Ross Camidge, Lecia V. Sequist, Eric B. Haura, Mark Ladanyi, Brenda F. Kurland, Kelly Kugler, John D. Minna, Paul A. Bunn and Mark G. Kris

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.29042

      The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. BRAF mutations occur in 2.2% of advanced-stage lung adenocarcinomas undergoing testing through the Lung Cancer Mutation Consortium, are most commonly V600E, and are associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas.

VIEW

  1. 1 - 100
  2. 101 - 135

SEARCH

SEARCH BY CITATION